HKUST Partners with Two Leading Shandong-Listed Pharma Companies
to Advance Novel Drug and Therapy Development (Chinese Only)
香港科技大學（科大）近日與山東兩大醫藥上市公司：綠葉製藥集團（綠葉製藥）與博安生物技術股份有限公司（博安生物）簽署合作協議，共同推動生物醫藥領域的前沿協作、成果轉化及人才培育，以支持科大發展醫療科技及申辦「香港生命健康研發院」等策略舉措。
深化前沿醫藥研究及人才培育合作
綠葉製藥是專注於創新藥物研發的領先中國醫藥企業，近年於中國內地、歐美、日本等主要醫藥市場成功上市13款新藥，在中樞神經系統（CNS）治療領域居領先地位。其子公司博安生物則是一家全面綜合性生物製藥公司，特別聚焦研發腫瘤、自身免疫、眼科和代謝疾病新藥及治療方法。根據協議內容，科大將與兩所企業就臨床前及臨床研究、前沿科學領域探索、人才培訓及交流和科研成果産業化等範疇展開深度協作。
其中，科大與博安生物將特別聚焦開發新型抗癌藥物和癌症新療法；與綠葉製藥則會集中研究神經科學與中樞神經系統疾病的新療法，以及先進藥物遞釋系統。此外，兩家企業亦將支持科大培育醫藥創新領域人才，為學生提供研究和實踐的產業基地，並提供相關科研技術落地應用平台。
科大副校長（研究及發展）鄭光廷教授樂見與兩間公司達成多領域合作，他表示：「科大一直致力推動科研成果產業化，積極搭建從實驗室走向市場的完善產業鏈。我們長期深耕生物醫藥領域的創新研究，近年更積極拓展醫療創新合作網絡。我們期待，透過結合AI與生物醫學的交叉優勢，科大可與兩家企業攜手協作，進一步推高產業化能力，並共同探索智能藥物開發、數據驅動的臨床研究等前沿方向，加速創新成果落地轉化，為全球帶來更精準、高效的醫療方案。」
促醫藥領域産學研一體化
綠葉製藥集團執行主席劉殿波先生表示：「一直以來，集團秉承『專業技術服務於人類健康』的使命，依託先進藥物遞釋系統全國重點實驗室，聚焦CNS等治療領域開展創新藥的研究與開發。我們很高興與科大達成戰略合作，期待雙方通過『產學研一體化』的深度融合，充分發揮各自在科研資源和創新成果產業化方面的優勢，共同加速創新成果轉化，尤其在CNS領域推動更多新療法的研究與臨床應用，服務於廣大患者極待滿足的醫療需求。」
博安生物首席执行官兼董事会主席姜華女士表示：「在全球生物科技加速迭代、健康需求持續升級的背景下，『產學研協同』已成為推動醫藥創新的重要力量。此次與科大達成戰略合作，雙方將結合各自在基礎科學研究與創新抗體開發平台的優勢，圍繞生物藥開發的新靶點、新技術及臨床研究與轉化等方面構建深度融合的創新生態。期待雙方的緊密協作，為全球患者帶來突破性的治療方案。」
近年來，科大積極推動創新醫療科技發展。自2024年初宣佈有意籌辦第三所醫學院以來，科大一直積極拓展合作網絡，至今已與超過20所海內外領先醫學院及醫療機構簽訂協議，涵蓋香港、大灣區、北京、長三角、華中地區、英國及美國等地。此外，科大亦正積極響應政府籌設「香港生命健康研發院」的舉措，期望可繼續發揮自身優勢，推動醫學科技領域的突破性進展，促進科研成果向臨床應用的高效轉化，裨益社會。
About The Hong Kong University of Science and Technology
The Hong Kong University of Science and Technology (HKUST) (https://hkust.edu.hk/) is a world-class university that excels in driving innovative education, research excellence, and impactful knowledge transfer. With a holistic and interdisciplinary pedagogy approach, HKUST was ranked 3rd in the Times Higher Education’s Young University Rankings 2024, 19th Worldwide and No.1 in Hong Kong in Times Higher Education’s impact Rankings. Thirteen HKUST subjects were ranked among the world’s top 50 in the QS World University Rankings by Subject 2025, with “Data Science and Artificial Intelligence” holding the 17th place, maintaining its position as first in Hong Kong. Our graduates are highly competitive, consistently ranking among the world’s top 30 most sought-after employees. In terms of research and entrepreneurship, over 80% of our work was rated “Internationally excellent” or “world leading” in the latest Research Assessment Exercise 2020 of Hong Kong’s University Grants Committee. As of May 2025, HKUST members have founded over 1,800 active start-ups, including 10 Unicorns and 17 exits (IPO or M&A)
About Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing, and sale of innovative medications. With R&D centers in China, the U.S., and Europe, the company has established its position as an international leader in novel drug delivery systems such as microspheres, liposomes, and transdermal patches. It also has multiple innovative products in two categories: new chemical entities and biologic antibodies. From 2021 to 2025, the company has had a total of 13 new drugs approved for marketing in one or multiple countries, including the U.S., several European countries, Japan, and China.
The company has 8 manufacturing facilities worldwide, which follow the internationally accepted, GMP-compliant quality management and control systems. To date, the company has launched over 30 products in the central nervous system (CNS), oncology, cardiovascular and other therapeutic areas. It conducts business in over 80 countries and regions, which include major pharmaceutical markets like China, the U.S., Europe, and Japan, and also include fast-growing emerging markets.
About Boan Biotech
Boan Biotech is a fully-integrated biopharmaceutical company developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform, ADC Technology Platform and Cell Therapy Platform.
For media enquiries, please contact:
Anita Lam
Tel: 2358 6313
Email: anitalam@ust.hk
Zheang ZHANG
Tel: 2358 6317
Email: joannezhang@ust.hk
Sign Up for Our Latest News
Latest News
The global transdisciplinary "research-to-operation" (R2O) initiative, “Seamless Prediction and Services for Sustainable Natural and Built Environments” (SEPRESS), led by The Hong Kong University of Science and Technology (HKUST), has been endorsed by the United Nations Educational, Scientific and Cultural Organization (UNESCO) as part of its International Decade of Sciences for Sustainable Development (IDSSD).
“HKUST-Sino One Million Dollar Entrepreneurship Competition 2025”, jointly organized by The Hong Kong University of Science and Technology (HKUST) and Sino Group, is now open for applications. Marking its 15th anniversary, this year’s competition offers a prize pool of over HK$1 million to empower winning teams in establishing or scaling their ventures.
Addressing the global financial sector’s surging demand for expertise in financial crimes and forensic accounting, the Hong Kong University of Science and Technology (HKUST) has partnered with KPMG and Griffith University to introduce Asia’s first Master of Science in Accounting (MSAC) program concentration dedicated these critical fields.